Deep Knowledge Group General Partner Dmitry Kaminskiy’s 2020 book, Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History, distilled the complex assembly of deep market intelligence and industry knowledge that Deep Knowledge Group and its Longevity-focused subsidiaries (including Longevity.Capital and Aging Analytics Agency) have developed over the previous 7 years into a full-scope understanding of the Global Longevity Industry, sufficient to define the industry for the first time and to reliably forecast its future development.
So much activity has happened since the publication of that book in 2020, both within the Global Longevity Industry generally and within Deep Knowledge Group itself, that the time has come not only to release an updated second edition of Longevity Industry 1.0, but to launch a dedicated series of follow-on books, including Biomarkers of Human Longevity (2021), Longevity Financial Industry (forthcoming), and Longevity Politics (forthcoming), and culminating in the release of its formal sequel, Longevity Industry 2.0 - DeepTech Engineering the Accelerated Trajectory of Human Longevity: The Blueprint and Pathway from Longevity Industry 1.0 to 2.0.
​
This series of books is based on Deep Knowledge Group’s characteristically data-driven and quantitative approach, and all of the specific domains they focus on will need tangible metrics for forecasting, analysis, progress-tracking, and measurement of outcomes for real-world execution. Their major aim is to help major industry decision makers on-board the practices and frameworks required maintain stable industry growth, bridge the Longevity Industry Liquidity Gap, enable actual Practical Human Longevity, neutralize the vast gap from model organisms to humans, and accelerate the socially-inclusive delivery of Longevity’s real-world humanitarian impacts for citizens and national economies.
Chapter 1. Top Facts and Myths About Longevity
Top 10 Longevity Myths
​
-
Aging doesn’t matter until you get old.
-
“Life extension” means being older for longer, prolonging your final years of frailty.
-
Longevity Industrialization will increase overpopulation.
-
Longevity Industrialization will lead to ecological collapse.
-
Healthy life extension will only be available to the wealthy.
-
Healthspan extension is still futuristic and experimental
-
I can’t do anything about my own Longevity today.
-
I’ll need to wait for the experimental medicines of the future to radically extend my own Healthy Longevity.
-
Doctors already know how to prolong Longevity. If there was more I could be doing, my doctor would have already told me about it.
-
Focusing on Longevity is selfish when we have so many other more pressing problems we should be working on.
Top 10 Counterintuitive Facts About Longevity
​
-
Longevity Industrialization is not a choice but a fundamental requirement for the future socioeconomic stability of humanity.
-
Practically functional Longevity technologies are available to consumers today.
-
The majority of Longevity companies operating today will not contribute to the real-world delivery of Practical Human Longevity.
-
Most Longevity investors actually know less about Longevity than you will after reading this book.
-
The increasing number of Longevity IPOs we are witnessing may have negative, rather than positive, long-term effects on Longevity Industry growth and stability.
-
Clinical trials are not the only way to validate Longevity technologies in humans.
-
Clinical trials are not even sufficient, by themselves, for the validation of Longevity technologies. Other frameworks (or significant clinical trial reforms) are required.
-
The Longevity Financial Industry is not just another sector of the Longevity Industry. It is the key to the industry’s further growth, maturation and stabilization.
-
Longevity Industrialization may solve the issues of overpopulation and eco logical collapse rather than intensify them.
-
Longevity will dominate politics and decide the fate of national elections by 2030. Government provision of HALE and QALY will become a fundamental citizen right.
Chapter 2. The Global Megatrend of Longevity Industrialization: The Rise of the Biggest and Most Complex Industry in Human History
-
Longevity Industrialization: 2010-2023
-
The Longevity Industry’s Journey From Geroscience R&D to the Very Frontier of Science, Technology, Advanced Biomedicine, Finance, and Governance
-
Longevity as the Biggest, Most Complex, and Most Ethical Industry in Human History
-
Windows of Opportunity: Longevity as the Inflection Point of the Biggest Challenges and Opportunities Facing National Economies in 2023-2030
Chapter 3. Formulating the Longevity Industry Framework: Data-Driven Frameworks To Define and Forecast the Megacomplex Longevity Industry
-
Longevity Industry Megacomplexity: Why Longevity Presents Novel and Unprecedented Challenges to Legacy Systems and Frameworks for Analytics, Forecasting, Benchmarking, and Effective Decision-Making
-
Multidimensional Approach for Reliable Analysis and Forecasting in the Megacomplex Longevity Industry
-
Longevity Industry Framework: Defining the Biggest and Most Complex Industry
Chapter 4. Global Longevity Industry 2023: State of the Market and Major Trends, Science, Technologies, Medicine, Investment, and Financial Landscape of the Longevity Industry in Q3 2023
Chapter 5. Longevity Industry Megacomplexity: Modern Data Science, AI Analytics, and Advanced IT Solutions To Manage Unprecedented Over-Complexity
-
Why Traditional BioTech Analytics Fail Against the Longevity Industry’s Extreme Complexity, Multidimensionality, and Technological Intersectionality
-
Current Disproportions in Global Longevity Industry Landscape: Investment, Entrepreneurship, Medicine, and Science
-
Longevity Analytics 2.0: Modern Data Science, AI Analytics, and IT Solutions To Manage, Define, and Forecast Longevity Complexity for Effective Decision-Making
-
Overview of Deep Knowledge Group Longevity Industry Big Data Analytical AI-Driven Systems and Dashboards
-
Modern Tools for De-Risking Investment, Accelerating R&D, Defining Hype vs. Reality, and Practicing Safe Human-Centered Validation in the Longevity Industry
Chapter 6. Longevity Science: Biomarkers of Human Longevity, AI and Data Science for Accelerating Aging Research and R&D, the Current State of Longevity Clinical Trials, and Defining Hype vs. Reality
-
The Rise of Longevity Science From Fringe Outlier Domain to the Very Frontier of the Most Advanced Biomedical Science
-
The Problem and Promise of Longevity Science: Opportunities and Risk Factors
-
Longevity Science: R&D Landscape Overview 2023
-
Current State of Longevity Clinical Trials
-
AI as the Major Accelerative Factor for Longevity Science R&D
-
Top Trends and Forecasts in Longevity Science: 2023
-
Ethical Imperatives for Longevity Scientists
Chapter 7. Longevity Biomarkers: The Critical Catalyst for Practical Human Longevity, Tangible Investment Decision-Making and De-Risking, and Longevity Industry Stabilization and Maturation
-
Biomarkers of Human Longevity: The Crucial Basis for Aging Research and R&D
-
Mice vs. Men and the Paradigm Shift in Scientific Community Mindset Toward Practical Human Validation
-
The Longevity Industry’s Biggest Systemic Risk: Reliance on Animal Validation
-
Tangible Investment Decision-Making and De-Risking
-
Data Science for Accelerating Aging Research and R&D
-
The Critical Catalyst for Practical Human Longevity
Chapter 8. Longevity Medicine: Practical Human Longevity
-
The Paradigm Shift From Treatment to Prevention
-
The Concept of Precision Health vs. Precision Medicine
-
From P1 Medicine to P6 Medicine: Predictive, Preventive, Precision, Participative, Psycho-Cognitive, Public
-
Practical Longevity: Market-Ready Technologies To Optimize Human Healthspan
-
Top Trends, Technologies, and Companies in Longevity Medicine: Q3 2023
Chapter 9. AgeTech and Silver Economy: The Multitrillion Opportunity of 1 Billion People in Retirement
-
AgeTech: A Massive Market-Ready Sector at the Direct Intersection of National Economies’ Most Pressing Challenges and Opportunities
-
The Longevity Tech Trifecta: The Coming Integration of AgeTech With WealthTech and HealthTech
-
Top Trends, Technologies, Apps, Devices, and Companies in AgeTech: Q3 2023
Chapter 10. Longevity Investment and Financial Industry: Health as the New Wealth and the Rise of Longevity FinTech, WealthTech, InsurTech, and Novel Longevity Finance
-
Health as the New Wealth
-
Longevity FinTech, WealthTech, and InsurTech
-
Longevity Investment and Financial AI-Driven Big Data Analytical System Dashboard of Deep Knowledge Group
-
Major Trends, Challenges, and Opportunities in Longevity Finance: Key Strategies for Pension Funds, Insurance Companies, Investment Banks, Asset Management Firms, and FinTech Companies
-
Bridging the Longevity Liquidity Gap: Unlocking Unlimited Investment Capital To Fuel the Next Stage of Longevity Industrialization
-
Financial Commoditization of Longevity Industrialization
-
Longevity Finance 2.0: Modern Longevity Financial Instruments and Derivatives, Investment Banks, Stock Exchanges, Composite Indexes, and ETFs
-
Top Trends, Technologies, and Companies in Longevity Finance: Q4 2023
Chapter 11. Longevity Policy and Governance: Longevity Technocracy and Longevity as the New Political Reality of the 21st Century
-
The Rise of Progressive Longevity MegaHubs and Technocracies
-
Benchmarking of National and Local Industrial Strategies, Policies, and Initiatives
-
Longevity as a New Political Priority for the 21st Century: How Citizens Will Demand the Delivery of Additional Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Years (QALY) From Their Governments and Politicians as a Basic Citizen Right by 2030
-
Longevity Governance Big Data Analytics Dashboard (SWOT Analysis, Continuous Monitoring, Regional Comparisons, and Practical Recommendation Packs)
-
Summary of Deep Knowledge Group Longevity Policy and Governance Activities
Chapter 12. The Concept of Longevity Valley: Case Study of Switzerland as the Potential World’s First Full-Scope Longevity Industry MegaHub (Co-Authored by Stefan Hascoet and Dmitry Kaminskiy)
.png)
-
Switzerland’s Unique Mix of Strengths: Advanced Biomedicine and Precision Health Industry Ecosystem and Internationally Renowned Financial Sector
-
Longevity Industry in Switzerland: Q3 2023
-
Switzerland’s Prospects To Become the World’s First True Full- Scope Longevity Industry MegaHub
-
Three Pillars of the Swiss Longevity Valley: Longevity Finance, Technology, and Progressive Governance
-
Summary of Deep Knowledge Group Swiss Longevity Activities: Developing the Swiss Longevity Valley
Chapter 13. Longevity Ethics: Frameworks for Optimizing the Socioeconomic Consequences and Humanitarian Dividends of Longevity Industrialization
-
The Ethical and Societal Pros and Cons of Increasing Longevity
-
Best- and Worst-Case Outcomes of Longevity Industrialization
Neutralizing Potential Negative Outcomes -
The Framework for Optimizing the Positive Outcomes and
Neutralizing the Negative Consequences of Global Longevity
Industrialization -
Social Psychology as the Major Roadblock or Accelerating Factor
-
Affecting the Societal and Ethical Outcomes of the Longevity
Industry -
Embracing the Engineering and DeepTech Mindset of Human
Technological and Industrial Development
Chapter 14. Technocratic Ethics: More Sophisticated Ethical Frameworks Are Required To Achieve the Real-World, Practical Dividends of Longevity Industrialization
-
Technological Progress Alone, While Extreme, Will Not Be Enough To Achieve Longevity Escape Velocity by 2030
-
Technocratic Utilitarianism: Why Standard Ethical Frameworks Are Irrelevant for Longevity Industrialization and Why More Sophisticated Ethical Metrics Are Needed
-
Why Decisive, Centralized Government Efforts To Bootstrap Socially-Inclusive Longevity Industrialization Create a Net- Positive Social Good for Humanity
-
If Pandemics Can Ethically Expand the Scope of Government Power To Prevent Death on a Global Scale, Why Are the 100.000 Deaths per Day Globally From Aging Any Different?
-
Accelerating Progress via Massively International “Manhattan Project” for Longevity: Technocratic Unity Using the Best Strengths of Each Nation
Chapter 15. Longevity Industry 2.0: DeepTech Engineering the Accelerated Trajectory of Human Longevity – the Blueprint and Pathway From Longevity Industry 1.0 to 2.0
-
The Evolution From Industry 1.0 (Defining the Industry) to Industry 2.0 (Applying the DeepTech Engineering Long-Term Strategy for Longevity Industrialization, Investment De-Risking, and National Longevity Economy Development)
-
The Evolution From Longevity Start-Ups to Multitrillion-Euro Longevity Corporations
-
The Future of Longevity Finance: Financial Instruments To Bridge the Longevity Liquidity Gap and Fuel the Next Stage of Global Longevity Industrialization
-
Financial Commoditization of Longevity Industry: New Longevity Markets, Instruments, Derivatives, Stock Exchanges, and ETFs To Unlock Multitrillion Growth Potential and True Industry Maturation
-
The Rise of Longevity Technocracies, Longevity Valleys, and Longevity States
-
Achieving Longevity Escape Velocity by 2030 Engineering the Positive Trajectory of Human Longevity
-
Longevity Industry in Switzerland: Q3 2023
About the Author
DMITRY KAMINSKIY
Dmitry Kaminskiy is an innovative entrepreneur, investor, author and philanthropist dedicated to impact investment and ethical business, with a focus on engineering the accelerated trajectory of progressive technological development for the benefit of humanity.
Mr. Kaminskiy is a co-founder and managing partner of Deep Knowledge Group - a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, Precision Medicine, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, policy and philanthropy.
-
He leads the activities of the consortium’s venture arms - Deep Knowledge Ventures, an investment fund focused on DeepTech and advanced science projects, and Longevity.Capital, which prioritizes the convergence of Longevity and Artificial Intelligence, areas in which it has unparalleled investment and exit strategies.
-
He is a frequent speaker on the topics of AI and Longevity, including conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, at the Future Finance Forum in Seoul “AI in Finance”, “Precision Medicine World Conference" in Silicon Valley, as well as several others at Oxford and Cambridge Universities.
Mr. Kaminskiy serves as managing trustee of Biogerontology Research Foundation, the UK’s oldest Longevity focused charity.